Opinions of independent non-executive directors
In accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”), and the governance standards for listed companies issued by the China Securities Regulatory Commission The guiding opinions on the establishment of independent director system in listed companies and other laws and regulations, as well as the relevant provisions of the articles of association of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. and the independent non-executive director system of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd, As an independent non-executive director of Shanghai Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) (Group) Co., Ltd. (hereinafter referred to as “the company”), The independent opinions on the proposal on the equity incentive plan for directors and core managers of Shanghai Fosun Health Technology (Group) Co., Ltd. (hereinafter referred to as “Fosun health”) (hereinafter referred to as “the plan”) considered at the 65th meeting of the eighth board of directors are as follows:
The plan complies with the company law, the securities law, the stock listing rules of Shanghai Stock Exchange, the Securities Listing Rules of the stock exchange of Hong Kong Limited and other relevant provisions, and the relevant pricing is fair and reasonable.
Since the incentive objects of the plan include the directors / senior managers of the company and several directors and supervisors of Fosun health, according to the provisions of the stock listing rules of Shanghai Stock Exchange and the Securities Listing Rules of the stock exchange of Hong Kong Limited, the relevant incentive objects constitute the related parties or connected persons of the company Its participation in the plan constitutes a connected / connected transaction of the company. The voting procedure of the board of directors on the plan (including this connected / connected transaction) is legal, and there is no situation that damages the interests of the company and its shareholders, especially the minority shareholders.
Independent non-executive directors: Li Ling, Tang Guliang, Wang Quandi, Yu Zishan February 11, 2002
